Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 132 articles:
HTML format
Text format



Single Articles


    April 2017
  1. THANGARAJAH F, Enninga I, Malter W, Hamacher S, et al
    A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
    Anticancer Res. 2017;37:1957-1964.
    PubMed     Text format     Abstract available


  2. INOUE Y, Yamashita N, Tokunaga E, Tanaka K, et al
    A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
    Anticancer Res. 2017;37:1917-1921.
    PubMed     Text format     Abstract available


  3. OKU Y, Nishiya N, Tsuda K, Shibazaki M, et al
    Dynamic Phenotypic Transition of Breast Cancer Cells In Vitro Revealed by Self-floating Cell Culture.
    Anticancer Res. 2017;37:1793-1797.
    PubMed     Text format     Abstract available


  4. BYSTRICKY B, Jurisova S, Karaba M, Minarik G, et al
    Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Anticancer Res. 2017;37:1787-1791.
    PubMed     Text format     Abstract available


  5. KIM KY, Park KI, Kim SH, Yu SN, et al
    Salinomycin Induces Reactive Oxygen Species and Apoptosis in Aggressive Breast Cancer Cells as Mediated with Regulation of Autophagy.
    Anticancer Res. 2017;37:1747-1758.
    PubMed     Text format     Abstract available


  6. DAS T, Nair RR, Green R, Padhee S, et al
    Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells.
    Anticancer Res. 2017;37:1655-1663.
    PubMed     Text format     Abstract available


  7. ACUNA UM, Curley RW Jr, Fatima N, Ahmed S, et al
    Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2017;37:1617-1623.
    PubMed     Text format     Abstract available


  8. JELINEK M, Kabelova A, Sramek J, Seitz J, et al
    Differing Mechanisms of Death Induction by Fluorinated Taxane SB-T-12854 in Breast Cancer Cells.
    Anticancer Res. 2017;37:1581-1590.
    PubMed     Text format     Abstract available


  9. CHIRICO A, Serpentini S, Merluzzi T, Mallia L, et al
    Self-efficacy for Coping Moderates the Effects of Distress on Quality of Life in Palliative Cancer Care.
    Anticancer Res. 2017;37:1609-1615.
    PubMed     Text format     Abstract available


    March 2017
  10. KIM HA, Kim JH, Choi HS, Kim YG, et al
    Core Needle Biopsy Specimens Are More Appropriate than Surgical Specimens for Evaluating the Expression of Phosphoproteins as Biological Markers in Invasive Breast Cancer.
    Anticancer Res. 2017;37:1409-1412.
    PubMed     Text format     Abstract available


  11. DIERAS V, Pop S, Berger F, Dujaric ME, et al
    First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Anticancer Res. 2017;37:1403-1407.
    PubMed     Text format     Abstract available


  12. WENDT C, Lindblom A, Arver B, VON Wachenfeldt A, et al
    Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    Anticancer Res. 2017;37:1257-1262.
    PubMed     Text format     Abstract available


  13. MACK N, Mazzio EA, Bauer D, Flores-Rozas H, et al
    Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.
    Anticancer Res. 2017;37:1205-1212.
    PubMed     Text format     Abstract available


  14. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  15. SEKIDO Y, Ohigashi S, Takahashi T, Hayashi N, et al
    Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
    Anticancer Res. 2017;37:1425-1431.
    PubMed     Text format     Abstract available


  16. IIZUKA D, Sasatani M, Barcellos-Hoff MH, Kamiya K, et al
    Hydrogen Peroxide Enhances TGFbeta-mediated Epithelial-to-Mesenchymal Transition in Human Mammary Epithelial MCF-10A Cells.
    Anticancer Res. 2017;37:987-995.
    PubMed     Text format     Abstract available


    February 2017
  17. ILENKO A, Sergent F, Mercuzot A, Zitoun M, et al
    Could Patients Older than 75 Years Benefit from a Systematic Breast Cancer Screening Program?
    Anticancer Res. 2017;37:903-907.
    PubMed     Text format     Abstract available


  18. LAWLER G, Leech M
    Dose Sparing Potential of Deep Inspiration Breath-hold Technique for Left Breast Cancer Radiotherapy Organs-at-risk.
    Anticancer Res. 2017;37:883-890.
    PubMed     Text format     Abstract available


  19. ESKELINEN M, Korhonen R, Selander T, Ollonen P, et al
    Beck Depression Inventory as a Predictor of Long-term Outcome Among Patients Admitted to the Breast Cancer Diagnosis Unit: A 25-year Cohort Study in Finland.
    Anticancer Res. 2017;37:819-824.
    PubMed     Text format     Abstract available


  20. WU HC, Southey MC, Hibshoosh H, Santella RM, et al
    DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    Anticancer Res. 2017;37:659-664.
    PubMed     Text format     Abstract available


  21. ONISHI H, Suyama K, Yamasaki A, Oyama Y, et al
    CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:561-565.
    PubMed     Text format     Abstract available


    January 2017

  22. Radiation Therapy Techniques and Treatment Planning for Breast Cancer.
    Anticancer Res. 2017;37:369-370.
    PubMed     Text format    



  23. The Pathobiology of Breast Cancer.
    Anticancer Res. 2017;37:365.
    PubMed     Text format    


  24. YANG X, DU G, Yu Z, Si Y, et al
    A Novel NHERF1 Mutation in Human Breast Cancer and Effects on Malignant Progression.
    Anticancer Res. 2017;37:67-73.
    PubMed     Text format     Abstract available


  25. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


  26. DAMASKOS C, Valsami S, Kontos M, Spartalis E, et al
    Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Anticancer Res. 2017;37:35-46.
    PubMed     Text format     Abstract available


  27. STRIEN L, Joensuu K, Heikkila P, Leidenius MH, et al
    Different Expression Patterns of CXCR4, CCR7, Maspin and FOXP3 in Luminal Breast Cancers and Their Sentinel Node Metastases.
    Anticancer Res. 2017;37:175-182.
    PubMed     Text format     Abstract available


  28. GIPPONI M, Baldelli I, Atzori G, Fregatti P, et al
    Tumescent Anesthesia in Skin- and Nipple-sparing Mastectomy: Results of a Prospective Clinical Study.
    Anticancer Res. 2017;37:349-352.
    PubMed     Text format     Abstract available


  29. SCHRODER L, Koch J, Mahner S, Kost BP, et al
    The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7).
    Anticancer Res. 2017;37:95-102.
    PubMed     Text format     Abstract available


    December 2016
  30. RAY A, Khong B, Khong HT
    A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6673-6676.
    PubMed     Text format     Abstract available


  31. LUKESOVA L, Vrana D, Svach I, Zlamalova N, et al
    Prognostic Influence of Internal Mammary Node Drainage in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2016;36:6641-6646.
    PubMed     Text format     Abstract available


  32. SAKAGUCHI K, Nakatsukasa K, Taguchi T
    Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6515-6519.
    PubMed     Text format     Abstract available


  33. TANAKA S, Iwamoto M, Kimura K, Takahashi Y, et al
    A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:6505-6509.
    PubMed     Text format     Abstract available


  34. TIAINEN L, Tanner M, Lahdenpera O, Vihinen P, et al
    Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6431-6438.
    PubMed     Text format     Abstract available


  35. RAMDANI LH, Talhi O, Taibi N, Delort L, et al
    Effects of Spiro-bisheterocycles on Proliferation and Apoptosis in Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:6399-6408.
    PubMed     Text format     Abstract available


  36. LEE J, Jung JH, Chae YS, Park HY, et al
    Long Noncoding RNA snaR Regulates Proliferation, Migration and Invasion of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2016;36:6289-6295.
    PubMed     Text format     Abstract available


  37. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Anticancer Res. 2016;36:6273-6277.
    PubMed     Text format     Abstract available


    November 2016
  38. SHINDEN Y, Kijima Y, Hirata M, Arima H, et al
    Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer.
    Anticancer Res. 2016;36:6173-6178.
    PubMed     Text format     Abstract available


  39. LEE SJ, Park BN, Roh JH, An YS, et al
    Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization.
    Anticancer Res. 2016;36:5975-5980.
    PubMed     Text format     Abstract available


  40. PIRES BR, DE Amorim IS, Souza LD, Rodrigues JA, et al
    Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment.
    Anticancer Res. 2016;36:5681-5691.
    PubMed     Text format     Abstract available


  41. VOUTSADAKIS IA
    Immune Blockade Inhibition in Breast Cancer.
    Anticancer Res. 2016;36:5607-5622.
    PubMed     Text format     Abstract available


    October 2016
  42. WALDREP AR, Avery EJ, Rose FF Jr, Midathada MV, et al
    Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:5389-5395.
    PubMed     Text format     Abstract available


  43. QIN W, Holick MF, Sorensen W, Walker CR, et al
    Vitamin D3 Treatment Influences PGE2 and TGFbeta in Normal and Increased Breast Cancer Risk Women.
    Anticancer Res. 2016;36:5347-5353.
    PubMed     Text format     Abstract available


  44. VILSMAIER T, Rack B, Konig A, Friese K, et al
    Influence of Circulating Tumour Cells on Production of IL-1alpha, IL-1beta and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.
    Anticancer Res. 2016;36:5227-5236.
    PubMed     Text format     Abstract available


  45. TAKEDA S, Okazaki H, Kudo T, Kakizoe K, et al
    Bongkrekic Acid as a Warburg Effect Modulator in Long-term Estradiol-deprived MCF-7 Breast Cancer Cells.
    Anticancer Res. 2016;36:5171-5182.
    PubMed     Text format     Abstract available


  46. GANGAPURAM M, Jean R, Mazzio E, Badisa R, et al
    Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
    Anticancer Res. 2016;36:5043-5052.
    PubMed     Text format     Abstract available


  47. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  48. STAHL JM, Hong JC, Lester-Coll NH, Kann BH, et al
    Chest Wall Deformity in the Radiation Oncology Clinic.
    Anticancer Res. 2016;36:5295-5300.
    PubMed     Text format     Abstract available


  49. FUJII T, Yajima R, Kurozumi S, Higuchi T, et al
    Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
    Anticancer Res. 2016;36:5481-5485.
    PubMed     Text format     Abstract available


    September 2016
  50. RIOS N, Adaskina N, Fromke C, Papendorf F, et al
    The Benefit of Baseline Staging-Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage.
    Anticancer Res. 2016;36:4909-14.
    PubMed     Text format     Abstract available


  51. KIM YJ, Kim K, Lee R, Kim J, et al
    Two-year Follow-up of Volumetric-modulated Arc Therapy for Treating Internal Mammary Nodes in Locally Advanced Breast Cancer.
    Anticancer Res. 2016;36:4847-51.
    PubMed     Text format     Abstract available


  52. HEPP P, Andergassen U, Jager B, Trapp E, et al
    Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Anticancer Res. 2016;36:4771-6.
    PubMed     Text format     Abstract available


  53. FURRER D, Jacob S, Caron C, Sanschagrin F, et al
    Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.
    Anticancer Res. 2016;36:4661-6.
    PubMed     Text format     Abstract available


  54. WAZIR U, El Hage Chehade H, Headon H, Oteifa M, et al
    Oncological Safety of Lipofilling in Patients with Breast Cancer: A Meta-analysis and Update on Clinical Practice.
    Anticancer Res. 2016;36:4521-8.
    PubMed     Text format     Abstract available


  55. KAPPIL M, Terry MB, Delgado-Cruzata L, Liao Y, et al
    Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4437-41.
    PubMed     Text format     Abstract available


  56. DO SI, Yoon G, Kim HS, Kim K, et al
    Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2016;36:4873-82.
    PubMed     Text format     Abstract available


    August 2016

  57. Handbook of HER2-Targeted Agents in Breast Cancer.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    


  58. KARLIKOVA M, Topolcan O, Narsanska A, Kucera R, et al
    Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study.
    Anticancer Res. 2016;36:4209-14.
    PubMed     Text format     Abstract available


  59. PIMENTEL C, Becquet M, Lavoue V, Henno S, et al
    Ovarian Metastases from Breast Cancer: A Series of 28 Cases.
    Anticancer Res. 2016;36:4195-200.
    PubMed     Text format     Abstract available


  60. KAPPIL MA, Liao Y, Terry MB, Santella RM, et al
    DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4039-44.
    PubMed     Text format     Abstract available


  61. CHIANG KC, Hsu SY, Lin SJ, Yeh CN, et al
    PTEN Insufficiency Increases Breast Cancer Cell Metastasis In Vitro and In Vivo in a Xenograft Zebrafish Model.
    Anticancer Res. 2016;36:3997-4005.
    PubMed     Text format     Abstract available


  62. FULAWKA L, Halon A
    Proliferation Index Evaluation in Breast Cancer Using ImageJ and ImmunoRatio Applications.
    Anticancer Res. 2016;36:3965-72.
    PubMed     Text format     Abstract available


  63. HOWARD CB, McDowell R, Feleke K, Deer E, et al
    Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts.
    Anticancer Res. 2016;36:3933-43.
    PubMed     Text format     Abstract available


  64. BENDRAT K, Fritz P, Muller S, Brockmoller S, et al
    Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Anticancer Res. 2016;36:3855-63.
    PubMed     Text format     Abstract available


  65. YANO S, Takehara K, Miwa S, Kishimoto H, et al
    In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation.
    Anticancer Res. 2016;36:3817-20.
    PubMed     Text format     Abstract available



  66. Breast Disease. Management and Therapies.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  67. LUCZYNSKA E, Heinze S, Adamczyk A, Rys J, et al
    Comparison of the Mammography, Contrast-Enhanced Spectral Mammography and Ultrasonography in a Group of 116 patients.
    Anticancer Res. 2016;36:4359-66.
    PubMed     Text format     Abstract available


  68. FUJII T, Yajima R, Kuwano H
    Implications of Long-term Indwelling of Tissue Expander in Breast Reconstruction: Risk of Expander Rupturing.
    Anticancer Res. 2016;36:4337-40.
    PubMed     Text format     Abstract available


    July 2016
  69. NAM SO, Yotsumoto F, Miyata K, Fukagawa S, et al
    Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.
    Anticancer Res. 2016;36:3651-7.
    PubMed     Text format     Abstract available


  70. SHIMAMURA Y, Tamatani D, Kuniyasu S, Mizuki Y, et al
    5-Aminolevulinic Acid Enhances Ultrasound-mediated Antitumor Activity via Mitochondrial Oxidative Damage in Breast Cancer.
    Anticancer Res. 2016;36:3607-12.
    PubMed     Text format     Abstract available


  71. CRISCITIELLO C, Bagnardi V, Viale G, Disalvatore D, et al
    HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.
    Anticancer Res. 2016;36:3537-40.
    PubMed     Text format     Abstract available


  72. SU CH, Lane HY, Hsiao CL, Liu LC, et al
    Matrix Metalloproteinase-1 Genetic Polymorphism in Breast Cancer in Taiwanese.
    Anticancer Res. 2016;36:3341-3345.
    PubMed     Text format     Abstract available


  73. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


    June 2016

  74. Novel Biomarkers in the Continuum of Breast Cancer.
    Anticancer Res. 2016;36:3224.
    PubMed     Text format    


  75. ANDERGASSEN U, Vogl A, Mumm JN, Kolbl AC, et al
    Immunocytochemical Characterization of Disseminated Tumour Cells from Bone Marrow of Breast Cancer Patients.
    Anticancer Res. 2016;36:3217-22.
    PubMed     Text format     Abstract available


  76. KOLBL AC, Brauer D, Hutter S, Rack B, et al
    New Marker Genes for Real-Time PCR-based Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients.
    Anticancer Res. 2016;36:3211-6.
    PubMed     Text format     Abstract available


  77. KOLBEN T, Hary T, Holdt LM, Schwarz TM, et al
    Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Anticancer Res. 2016;36:3185-90.
    PubMed     Text format     Abstract available


  78. FREIER CP, Kuhn C, Endres S, Mayr D, et al
    FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.
    Anticancer Res. 2016;36:3139-45.
    PubMed     Text format     Abstract available


  79. KONIG A, Vilsmaier T, Rack B, Friese K, et al
    Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
    Anticancer Res. 2016;36:3123-30.
    PubMed     Text format     Abstract available


  80. FUJII T, Yajima R, Tsuboi M, Higuchi T, et al
    Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.
    Anticancer Res. 2016;36:3019-22.
    PubMed     Text format     Abstract available


  81. SHIMA H, Kutomi G, Satomi F, Maeda H, et al
    SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Anticancer Res. 2016;36:2945-53.
    PubMed     Text format     Abstract available


  82. BRAUTIGAM K, Mitzlaff K, Uebel L, Koster F, et al
    Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Anticancer Res. 2016;36:2759-66.
    PubMed     Text format     Abstract available


  83. SCHELZ Z, Ocsovszki I, Bozsity N, Hohmann J, et al
    Antiproliferative Effects of Various Furanoacridones Isolated from Ruta graveolens on Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2751-8.
    PubMed     Text format     Abstract available


  84. KASSAYOVA M, Bobrov N, Strojny L, Orendas P, et al
    Anticancer and Immunomodulatory Effects of Lactobacillus plantarum LS/07, Inulin and Melatonin in NMU-induced Rat Model of Breast Cancer.
    Anticancer Res. 2016;36:2719-28.
    PubMed     Text format     Abstract available


  85. KIM JY, Heo SH, Song IH, Park IA, et al
    Activation of the PERK-eIF2alpha Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer.
    Anticancer Res. 2016;36:2705-11.
    PubMed     Text format     Abstract available


  86. MIN DJ, He S, Green JE
    Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2649-57.
    PubMed     Text format     Abstract available


    May 2016
  87. JANSSEN S, Glanzmann C, Lang S, Verlaan S, et al
    Hypofractionated Radiotherapy for Breast Cancer Including Risk-adapted Boost: Update on Tolerance and Efficacy of an Accelerated START A Regime.
    Anticancer Res. 2016;36:2513-22.
    PubMed     Text format     Abstract available


  88. TARDIOLI S, Ballesio L, Gigli S, DI Pastena F, et al
    Wire-guided Localization in Non-palpable Breast Cancer: Results from Monocentric Experience.
    Anticancer Res. 2016;36:2423-7.
    PubMed     Text format     Abstract available


  89. LAKIS S, Dimoudis S, Kotoula V, Alexopoulou Z, et al
    Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.
    Anticancer Res. 2016;36:2365-78.
    PubMed     Text format     Abstract available


  90. JUECKSTOCK J, Burkhardt N, Kuhn C, Blankenstein T, et al
    Expression of Activin During and After Chemotherapy in Peripheral Blood of Patients with Primary Breast Cancer.
    Anticancer Res. 2016;36:2153-9.
    PubMed     Text format     Abstract available


    April 2016

  91. Breast Cancer. Methods and Protocols.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    


  92. SOUZA AC, DA Silva VH, Seixas C, DE Oliveira Scudeller TT, et al
    Cytogenetic Biomonitoring in Buccal Mucosa Cells from Women Submitted to Chemotherapy After Mastectomy for Breast Cancer.
    Anticancer Res. 2016;36:1955-8.
    PubMed     Text format     Abstract available


  93. CARONONGAN A 3RD, Venturini B, Canuti D, Dlay S, et al
    Neural Analyses Validate and Emphasize the Role of Progesterone Receptor in Breast Cancer Progression and Prognosis.
    Anticancer Res. 2016;36:1909-15.
    PubMed     Text format     Abstract available


  94. FUJII T, Yajima R, Tatsuki H, Kuwano H, et al
    Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Anticancer Res. 2016;36:1785-9.
    PubMed     Text format     Abstract available


  95. EL HAGE CHEHADE H, Headon H, Kasem A, Mokbel K, et al
    Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    Anticancer Res. 2016;36:1461-71.
    PubMed     Text format     Abstract available


  96. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  97. RAPOSO TP, Beirao BC, Pires I, Prada J, et al
    Immunohistochemical Expression of CCR2, CSF1R and MMP9 in Canine Inflammatory Mammary Carcinomas.
    Anticancer Res. 2016;36:1805-13.
    PubMed     Text format     Abstract available


  98. MOSS T, Chirico A, Mallia L, Lucidi F, et al
    Psychosocial Outcomes of Quadrantectomy Versus Mastectomy in a Southern Italian Sample: Development and Needs of the Italian Derriford Appearance Scale 24.
    Anticancer Res. 2016;36:1519-26.
    PubMed     Text format     Abstract available


    March 2016
  99. QIAO G, Cong Y, Zou H, Lin J, et al
    False-negative Frozen Section of Sentinel Lymph Node Biopsy in a Chinese Population with Breast Cancer.
    Anticancer Res. 2016;36:1331-7.
    PubMed     Text format     Abstract available


  100. MALIK MF, Satherley LK, Davies EL, Ye L, et al
    Expression of Semaphorin 3C in Breast Cancer and its Impact on Adhesion and Invasion of Breast Cancer Cells.
    Anticancer Res. 2016;36:1281-6.
    PubMed     Text format     Abstract available


  101. ZHAO H, Martin TA, Davies EL, Ruge F, et al
    The Clinical Implications of RSK1-3 in Human Breast Cancer.
    Anticancer Res. 2016;36:1267-74.
    PubMed     Text format     Abstract available


  102. JIANG A, Zhao H, Cai J, Jiang WG, et al
    Possible Effect of Muscle-relaxant Anaesthetics on Invasion, Adhesion and Migration of Breast Cancer Cells.
    Anticancer Res. 2016;36:1259-65.
    PubMed     Text format     Abstract available


  103. ZHAO M, Jia W, Jiang WG, Wang P, et al
    ADAM29 Expression in Human Breast Cancer and its Effects on Breast Cancer Cells In Vitro.
    Anticancer Res. 2016;36:1251-8.
    PubMed     Text format     Abstract available


  104. YUE LU, Xiang JY, Sun P, Yao YS, et al
    Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance.
    Anticancer Res. 2016;36:1243-9.
    PubMed     Text format     Abstract available


  105. YANG X, Si Y, Tao T, Martin TA, et al
    The Impact of TIMM17A on Aggressiveness of Human Breast Cancer Cells.
    Anticancer Res. 2016;36:1237-41.
    PubMed     Text format     Abstract available


  106. SATHERLEY LK, Sun PH, Ji KE, Mason M, et al
    Prostate Apoptosis Response-4 (PAR4) Suppresses Growth and Invasion of Breast Cancer Cells and Is Positively Associated with Patient Survival.
    Anticancer Res. 2016;36:1227-35.
    PubMed     Text format     Abstract available


  107. DU G, Hao C, Gu Y, Wang Z, et al
    A Novel NHERF1 Mutation in Human Breast Cancer Inactivates Inhibition by NHERF1 Protein in EGFR Signaling.
    Anticancer Res. 2016;36:1165-73.
    PubMed     Text format     Abstract available


  108. BRADBURY R, Jiang WG, Cui YX
    MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases.
    Anticancer Res. 2016;36:1143-51.
    PubMed     Text format     Abstract available


  109. RADES D, Dziggel L, Janssen S, Blanck O, et al
    A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer.
    Anticancer Res. 2016;36:1073-6.
    PubMed     Text format     Abstract available


  110. KIM HA, Seong MK, Kim JH, Kim YG, et al
    Prognostic Value of Anti-Mullerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer.
    Anticancer Res. 2016;36:1051-7.
    PubMed     Text format     Abstract available


  111. SCHNEEWEISS A, Forster F, Tesch H, Aktas B, et al
    First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
    Anticancer Res. 2016;36:967-74.
    PubMed     Text format     Abstract available


  112. CUI YX, Evans BA, Jiang WG
    New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
    Anticancer Res. 2016;36:1193-201.
    PubMed     Text format     Abstract available


    February 2016
  113. AMABILE MI, Monti M, Merola R, Frusone F, et al
    Nipple-sparing Mastectomy in Patients with Preoperative Diagnosis of Non-invasive Breast Carcinoma. A Single-center Experience.
    Anticancer Res. 2016;36:779-83.
    PubMed     Text format     Abstract available


  114. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016

  115. Precision Molecular Pathology of Breast Cancer.
    Anticancer Res. 2016;36:479-80.
    PubMed     Text format    


  116. DIORIO C, Furrer D, Michaud A, Laberge S, et al
    Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry for Breast Cancer.
    Anticancer Res. 2016;36:435-7.
    PubMed     Text format     Abstract available


  117. ALMSTEDT K, Fasching PA, Scharl A, Rauh C, et al
    Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
    Anticancer Res. 2016;36:419-25.
    PubMed     Text format     Abstract available


  118. KAIRALUOMA P, Mattson J, Heikkila P, Pere P, et al
    Perioperative Paravertebral Regional Anaesthesia and Breast Cancer Recurrence.
    Anticancer Res. 2016;36:415-8.
    PubMed     Text format     Abstract available


  119. FUJII T, Yajima R, Tatsuki H, Oosone K, et al
    Implication of 18F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Anticancer Res. 2016;36:393-7.
    PubMed     Text format     Abstract available


  120. SHI Z, Peddi P, Burton G, Mills G, et al
    Effect of Postmastectomy Radiation on Survival of AJCC pN2/N3 Breast Cancer Patients.
    Anticancer Res. 2016;36:261-9.
    PubMed     Text format     Abstract available


  121. SMITH TA, Phyu SM, Akabuogu EU
    Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
    Anticancer Res. 2016;36:87-93.
    PubMed     Text format     Abstract available


  122. GITT A, Bose-Ribeiro H, Nieder C, Kup PG, et al
    Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation.
    Anticancer Res. 2016;36:355-60.
    PubMed     Text format     Abstract available


    December 2015
  123. MANSO L, Palomo AG, Carrion RP, Cassinello J, et al
    Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
    Anticancer Res. 2015;35:6941-50.
    PubMed     Text format     Abstract available


  124. BACALBASA N, Balescu I, Dima S, Popescu I, et al
    Long-term Survivors After Liver Resection for Breast Cancer Liver Metastases.
    Anticancer Res. 2015;35:6913-7.
    PubMed     Text format     Abstract available


  125. BACALBASA N, Balescu I, Dima S, Popescu I, et al
    The Role of Re-resection for Breast Cancer Liver Metastases-a Single Center Experience.
    Anticancer Res. 2015;35:6877-80.
    PubMed     Text format     Abstract available


  126. RECCHIA F, Candeloro G, Rosselli M, Bratta M, et al
    Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
    Anticancer Res. 2015;35:6847-53.
    PubMed     Text format     Abstract available


  127. DZIGGEL L, Dahlke M, Janssen S, Hornung D, et al
    Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer.
    Anticancer Res. 2015;35:6793-7.
    PubMed     Text format     Abstract available


  128. WATROWSKI R, Castillo-Tong DC, Wolf A, Schuster E, et al
    HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
    Anticancer Res. 2015;35:6667-70.
    PubMed     Text format     Abstract available


  129. SADOVSKA L, Eglitis J, Line A
    Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer.
    Anticancer Res. 2015;35:6379-90.
    PubMed     Text format     Abstract available


    November 2015
  130. MAIER GS, Horas K, Kurth AA, Lazovic D, et al
    Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
    Anticancer Res. 2015;35:6281-5.
    PubMed     Text format     Abstract available


  131. KLAIRMONT M, Kopkash K, Favuzza J, Hill M, et al
    Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus.
    Anticancer Res. 2015;35:6159-62.
    PubMed     Text format     Abstract available


  132. VAN MOURIK TR, Lappchen T, Rossin R, VAN Beijnum JR, et al
    Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis.
    Anticancer Res. 2015;35:5945-54.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: